الفهرس Only 14 pages are availabe for public view
 |  | from | 112 |  |  |
| | | from | 112 | | |
Abstract
Hepatitis C virus (HCV) is a major public health problem and is considered the most common etiology of chronic liver disease in Egypt. Many studies were conducted to find accurate prediction of response prior to initiation of therapy. Aim of work: To prove serum MxA 88, 123 polymorphism if can be used as a predictor of response to treatment of chronic HCV Egyptian patients. Patients and methods: The study was conducted on 94 patients with chronic HCV who received pegylated interferon & ribavirin. And 20 healthy subjectsall patients were subjected to pretreatment routine laboratory evaluation and pretreatment serum MxA88, 123polymorphism. Results:the presence of MxA88GGor MxA123CC is a significant for the non-response and there was statistical significant association between response for treatment and albumin, AST, ALT, AFP, bilirubin, Platelets Conclusion: Pretreatment serum MxA 88, 123 polymorphismcan be used as a predictor of response to combination therapy in chronic HCV Egyptian patients